Literature DB >> 18787617

Morphoproteomics: a novel approach to identify potential therapeutic targets in cancer patients.

Dongfeng Tan.   

Abstract

Entities:  

Year:  2008        PMID： 18787617      PMCID： PMC2480548     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN： 1936-2625


× No keyword cloud information.
  10 in total

Review 1.  Cancer burden in the year 2000. The global picture.

Authors:  D M Parkin; F I Bray; S S Devesa
Journal:  Eur J Cancer       Date:  2001-10       Impact factor: 9.162

2.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

3.  Microarrays and clinical investigations.

Authors:  Edison T Liu; Krishna R Karuturi
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

Review 4.  Complex roles of tissue inhibitors of metalloproteinases in cancer.

Authors:  Yangfu Jiang; Itzhak D Goldberg; Y Eric Shi
Journal:  Oncogene       Date:  2002-03-28       Impact factor: 9.867

5.  Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications.

Authors:  Robert E Brown; Amy Law
Journal:  Ann Clin Lab Sci       Date:  2006       Impact factor: 1.256

6.  Morphoproteomic portrait of the mTOR pathway in mesenchymal chondrosarcoma.

Authors:  Robert E Brown
Journal:  Ann Clin Lab Sci       Date:  2004       Impact factor: 1.256

7.  Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer.

Authors:  Robert E Brown; George Zotalis; Ping L Zhang; Bihong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 8.  Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.

Authors:  Janet E Dancey
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

9.  Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.

Authors:  H G van der Poel
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

10.  Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in high risk neuro-blastoma, with cell cycle and protein analyte correlates.

Authors:  Robert E Brown; Dongfeng Tan; Jeffrey S Taylor; Michal Miller; Jeffrey W Prichard; Marylee M Kott
Journal:  Ann Clin Lab Sci       Date:  2007       Impact factor: 1.256
  10 in total
  2 in total

Review 1.  Proteomic approaches to investigate gammaherpesvirus biology and associated tumorigenesis.

Authors:  Danielle L Chappell; Maria C White; Blossom Damania
Journal:  Adv Virus Res       Date:  2020-11-09       Impact factor: 9.937

2.  Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma.

Authors:  Noah E Berlow; Catherine S Grasso; Michael J Quist; Mingshan Cheng; Regina Gandour-Edwards; Brian S Hernandez; Joel E Michalek; Christopher Ryan; Paul Spellman; Ranadip Pal; Lynn S Million; Mark Renneker; Charles Keller
Journal:  Sarcoma       Date:  2020-05-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.